Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries

Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries

Introduction: During the coronavirus disease 2019 (COVID-19) pandemic, low- and middle- income countries had less access to monoclonal antibodies, such as tocilizumab (TCZ), compared to high-income countries. This retrospective cohort study aimed at evaluating the impact of a delayed TCZ administra...

Full description

Saved in:
Bibliographic Details
Main Authors: Branko Beronja, Olja Stevanović, Nataša Nikolić, Nikola Mitrović, Tatjana Gazibara, Nevena Todorović, Ana Filipović, Jelena Dotlic, Mihailo Stjepanović, Jelena Simić, Ivana Milosevic
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2025-02-01
Series:Journal of Infection in Developing Countries
Subjects:
COVID-19
tocilizumab
delay
mortality
intensive care unit
Online Access:https://jidc.org/index.php/journal/article/view/19914
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jidc.org/index.php/journal/article/view/19914

Similar Items